Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Quidel Expects Q1 Revenues To More Than Double On Higher COVID-19 Test Sales

Quidel Corp (NASDAQ:QDELexpects Q1 FY22 sales of $990 million - $1 billion, up 164% - 166% Y/Y, beating the consensus of $817.30 million.

  • The company expects COVID-19 product revenues of $836 million, including approximately $657 million in QuickVue COVID-19 test revenue and roughly $138 million in Sofia SARS antigen test revenue.
  • "In the first quarter of 2022, we sold approximately 113 million QuickVue COVID-19 antigen tests and about 12 million Sofia SARS antigen tests," said Douglas Bryant, President, and CEO.
  • Also Read: Quidel's Q4 Earnings Beat Street View Despite 21% Decline In Sales.
  • "We also expanded our installed base of Sofia analyzers to 79,000 instrument placements, which further widens our point-of-care footprint and increases opportunities to introduce our full portfolio of assays to patients and healthcare providers," Bryant added.
  • Price Action: QDEL shares closed 0.39% higher at $118.10 during after-hours trading on Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.